Tardive Dyskinesia (TD) Treatment Drugs market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Tardive Dyskinesia (TD) Treatment Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Tardive Dyskinesia (TD) Treatment Drugs market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Valbenazine
Deutetrabenazine
Segment by Application
Hospitals
Clinic
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Neurocrine Biosciences, Inc.
Teva Pharmaceutical Industries
Pfizer Inc.
Biogen
Novartis AG
AstraZeneca
GlaxoSmithKline plc.
Bayer AG
Sanofi
